SystImmune Revenue and Competitors

Seattle, WA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SystImmune's estimated annual revenue is currently $15.5M per year.(i)
  • SystImmune's estimated revenue per employee is $155,000

Employee Data

  • SystImmune has 100 Employees.(i)
  • SystImmune grew their employee count by 52% last year.

SystImmune's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Clinical DevelopmentReveal Email/Phone
3
VP, Immuno-OncologyReveal Email/Phone
4
VP, Finance & Business OperationsReveal Email/Phone
5
SVP, Finance & Business OperationsReveal Email/Phone
6
Associate Director Medical WritingReveal Email/Phone
7
Sr Director Clinical OperationsReveal Email/Phone
8
Senior Project ManagerReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
Principal Scientist IIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$3.3M4310%$101MN/A
#4
$5.7M3712%N/AN/A
#5
$7M4541%N/AN/A
#6
$1.7M22-8%N/AN/A
#7
$3.9M504%$10.1MN/A
#8
$1.9M12-73%N/AN/A
#9
$29.3M151-17%$148MN/A
#10
$2M1386%N/AN/A
Add Company

What Is SystImmune?

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

keywords:N/A

N/A

Total Funding

100

Number of Employees

$15.5M

Revenue (est)

52%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$29.3M10113%N/A
#2
$27.8M10320%N/A
#3
$29.9M10316%N/A
#4
$10.5M103-2%N/A
#5
$31M10723%N/A